Home/Pipeline/RO-7077169

RO-7077169

Atopic Dermatitis

Phase 2Active

Key Facts

Indication

Atopic Dermatitis

Phase

Phase 2

Status

Active

Company

Rohto Pharmaceutical

About Rohto Pharmaceutical

Founded in 1899, Rohto Pharmaceutical has built a dominant global franchise in consumer healthcare, particularly in eye drops and skincare, generating stable revenues and deep consumer trust. The company's core strategy involves using this financial strength to fund a strategic pivot into biopharmaceutical R&D, with a focused pipeline in ophthalmology, dermatology, and metabolic diseases. Its achievements include a formidable OTC brand portfolio, international distribution, and the advancement of several drug candidates, positioning it for long-term growth beyond its traditional market.

View full company profile

Therapeutic Areas

Ophthalmology Dermatology Immunology Metabolic Disease

Other Atopic Dermatitis Drugs

Drug	Company	Phase	Status
PEP Biologic™	Intent Biologics	Unknown	Active
HBM7575 (SKB575)	Harbour BioMed	IND Filed	Active (Global)
ITK inhibitor	Acellera	Pre-clinical	Hit-to-Lead
ENS-002 (Fermata Derm)	Concerto Biosciences	Pre-clinical	Active
Lead Program	MatriSys Bioscience	Phase 1	Active
Atopic Dermatitis Trial	Well Pharma Medical Research	Not Specified	Active
MEndoB	Micreos	Pre-clinical	Active
Atopic Dermatitis Program	Lxbio Pharmaceuticals	Pre-clinical	Active
B244	AOBiome	Phase 3	Active
CTO1681	CytoAgents	Pre-clinical	Active
DS107	DS Biopharma	Phase 2	Active
AX-158	Artax Biopharma	Phase 2	Active